Analysis of p53-regulated gene expression patterns using oligonucleotide arrays

Genes and Development

Volumn 14, Issue 8, 2000, Pages 981-993

  Zhao, Renbin ^a   Gish, Kurt ^c   Murphy, Maureen ^b   Yin, Yuxin ^d   Notterman, Daniel ^a   Hoffman, William H ^b   Tom, Edward ^c   Mack, David H ^c   Levine, Arnold J ^e  

^a PRINCETON UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c Eos Biotechnology   (United States)

^d Columbia University ^*  (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

Author keywords

EB 1 cells; Oligonucleotide microarrays; p53 regulated genes

Indexed keywords

MESSENGER RNA; OLIGONUCLEOTIDE; PROTEIN P53; TRANSCRIPTION FACTOR; ZINC;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL TYPE; COLON CARCINOMA; CONTROLLED STUDY; CYTOSKELETON; DNA DAMAGE; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE;

CHLORIDES; CLUSTER ANALYSIS; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENES, P53; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; ZINC COMPOUNDS;

EID: 0034656243     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Alon, U., N. Barkai, D.A. Notterman, K. Gish, S. Ybarra, D. Mack, and A.J. Levine. 1999. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl. Acad. Sci. 96: 6745-6750.
2. Baker, S.J., S. Markowitz, E.R. Fearon, J.K. Willson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915.
3. Banin, S., L. Moyal, S. Shieh, Y. Taya, C.W. Anderson, L. Chessa, N.I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677.
4. Bargonetti, J., J.J. Manfredi, X. Chen, D.R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes & Dev. 7: 2565-2574.
5. Bennett, W.P., M.C. Hollstein, I.C. Hsu, D. Sidransky, D.P. Lane, B. Vogelstein, and C.C. Harris. 1992. Mutational spectra and immunohistochemical analyses of p53 in human cancers. Chest 101: 19S-20S.
6. Canman, C.E., D.S. Lim, K.A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. Appella, M.B. Kastan, and J.D. Siliciano. 1998. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679.
7. Cho, Y., S. Gorina, P.D. Jeffrey, and N.P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346-355.
8. de Stanchina, E., M.E. McCurrach, F. Zindy, S.Y. Shieh, G. Ferbeyre, A.V. Samuelson, C. Prives, M.F. Roussel, C.J. Sherr, and S.W. Lowe. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes & Dev. 12: 2434-2442.
9. DeRisi, J.L., V.R. Iyer, and P.O. Brown. 1997. Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 278: 680-686.
10. Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery, Jr., J.S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
11. Eisen, M.B., P.T. Spellman, P.O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. 95: 14863-14868.
12. el-Deiry, W.S., S.E. Kern, J.A. Pietenpol, K.W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1: 45-49.
13. el-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
14. Eliyahu, D., D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren. 1989. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. 86: 8763-8767.
15. Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Prywes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature 358: 83-86.
16. Fiedler, K., F. Lafont, R.G. Parton, and K. Simons. 1995. Annexin XIIIb: A novel epithelial specific annexin is implicated in vesicular traffic to the apical plasma membrane. J. Cell Biol. 128: 1043-1053.
17. Fields, S. and S.K. Jang. 1990. Presence of a potent transcription activating sequence in the p53 protein. Science 249: 1046-1049.
18. Finlay, C.A., P.W. Hinds, and A.J. Levine. 1989. The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083-1093.
19. Guan, L.S., M. Rauchman, and Z.Y. Wang. 1998. Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition. J. Biol. Chem. 273: 27047-27050.
20. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
21. Hermeking, H., C. Lengauer, K. Polyak, T.C. He, L. Zhang, S. Thiagalingam, K.W. Kinzler, and B. Vogelstein. 1997. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1: 3-11.
22. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 mutations in human cancers. Science 253: 49-53.
23. Iwabuchi, K., B. Li, P. Bartel, and S. Fields. 1993. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene 8: 1693-1696.
24. Iyer, V.R., M.B. Eisen, D.T. Ross, G. Schuler, T. Moore, J.C.F. Lee, J.M. Trent, L.M. Staudt, J. Hudson, Jr., M.S. Boguski, D. Lashkari, D. Shalon, D. Botstein, and P.O. Brown. 1999. The transcriptional program in the response of human fibroblasts to serum. Science 283: 83-87.
25. Jayaraman, L., K.G. Murthy, C. Zhu, T. Curran, S. Xanthoudakis, and C. Prives. 1997. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes & Dev. 11: 558-570.
26. Kern, S.E., K.W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711.
27. Khanna, K.K., K.E. Keating, S. Kozlov, S. Scott, M. Gatei, K. Hobson, Y. Taya, B. Gabrielli, D. Chan, S.P. Lees-Miller, and M.F. Lavin. 1998. ATM associates with and phosphorylates p53: Mapping the region of interaction. Nat. Genet. 20: 398-400.
28. Kim, T.A., J. Lim, S. Ota, S. Raja, R. Rogers, B. Rivnay, H. Avraham, and S. Avraham. 1998. NRP/B, a novel nuclear matrix protein, associates with p110(RB) and is involved in neuronal differentiation. J. Cell Biol. 141: 553-566.
29. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
30. Liebermann, D. A. and B. Hoffman. 1998. MyD genes in negative growth control. Oncogene 17: 3319-3329.
31. Lin, J., J. Chen, B. Elenbaas, and A.J. Levine. 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes & Dev. 8: 1235-1246.
32. Lockhart, D.J., H. Dong, M.C. Byrne, M.T. Follettie, M.V. Gallo, M.S. Chee, M. Mittmann, C. Wang, M. Kobayashi, H. Horton, and E.L. Brown. 1996. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 14: 1675-1680.
33. Lomax, K.J., T.L. Leto, H. Nunoi, J.I. Gallin, and H.L. Malech. 1989. Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science 245: 409-412.
34. Lozano, G. and G. Liu. 1998. Mouse models dissect the role of p53 in cancer and development. Semin. Cancer Biol. 8: 337-344.
35. Lu, H., Y. Taya, M. Ikeda, and A.J. Levine. 1998. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc. Natl. Acad. Sci. 95: 6399-6402.
36. Mack, D.H., J. Vartikar, J.M. Pipas, and L.A. Laimins. 1993. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363: 281-283.
37. Malkin, D., F.P. Li, L.C. Strong, J.F. Fraumeni, Jr., C.E. Nelson, D.H. Kim, J. Kassel, M.A. Gryka, F.Z. Bischoff, M.A. Tainsky et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
38. McGall, G., J. Labadie, P. Brock, G. Wallraff, T. Nguyen, and W. Hinsberg. 1996. Light-directed synthesis of high-density oligonucleotide arrays using semiconductor photoresists. Proc. Natl. Acad. Sci. 93: 13555-13560.
39. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671-680.
40. Muller, M., S. Wilder, D. Bannasch, D. Israeli, K. Lehlbach, M. Li-Weber, S.L. Friedman, P.R. Galle, W. Stremmel, M. Oren, and P.H. Krammer. 1998. p53 activates the CD95 (APO-1/ Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188: 2033-2045.
41. Murphy, M., A. Hinman, and A.J. Levine. 1996. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes & Dev. 10: 2971-2980.
42. Parton, R.G. 1996. Caveolae and caveolins. Curr. Opin. Cell Biol. 8: 542-548.
43. Pavletich, N.P., K.A. Chambers, and C.O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes & Dev. 7: 2556-2564.
44. Pietenpol, J.A., T. Tokino, S. Thiagalingam, W.S. el-Deiry, K.W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. 91: 1998-2002.
45. Polyak, K., Y. Xia, J.L. Zweier, K.W. Kinzler, and B. Vogelstein. 1997. A model for p53-induced apoptosis. Nature 389: 300-305.
46. Prives, C. and P.A. Hall. 1999. The p53 pathway. J. Pathol. 187: 112-126.
47. Raycroft, L., H.Y. Wu, and G. Lozano. 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249: 1049-1051.
48. Schena, M., D. Shalon, R.W. Davis, and P.O. Brown. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470.
49. Seto, E., A. Usheva, G.P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A.J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. 89: 12028-12032.
50. Shaw, P., R. Bovey, S. Tardy, R. Sahli, B. Sordat, and J. Costa. 1992. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. 89: 4495-4499.
51. Siderovski, D.P., S.P. Heximer, and D.R. Forsdyke. 1994. A human gene encoding a putative basic helix-loop-helix phosphoprotein whose mRNA increases rapidly in cycloheximide-treated blood mononuclear cells. DNA Cell Biol. 13: 125-147.
52. Tao, W. and A.J. Levine. 1999. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. 96: 6937-6941.
53. Unger, T., M.M. Nau, S. Segal, and J.D. Minna. 1992. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11: 1383-1390.
54. Wang, P., M. Reed, Y. Wang, G. Mayr, J.E. Stenger, M.E. Anderson, J.F. Schwedes, and P. Tegtmeyer. 1994. p53 domains: Structure, oligomerization, and transformation. Mol. Cell. Biol. 14: 5182-5191.
55. Wang, Y., M. Reed, P. Wang, J.E. Stenger, G. Mayr, M.E. Anderson, J.F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: Identification and characterization of two autonomous DNA-binding regions. Genes & Dev. 7: 2575-2586.
56. Wodicka, L., H. Dong, M. Mittmann, M.H. Ho, and D.J. Lockhart. 1997. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat. Biotechnol. 15: 1359-1367.
57. Wu, G.S., T.F. Burns, E.R. McDonald III, W. Jiang, R. Meng, I.D. Krantz, G. Kao, D.D. Gan, J.Y. Zhou, R. Muschel, S.R. Hamilton, N.B. Spinner, S. Markowitz, G. Wu, and W.S. el-Deiry. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17: 141-143.
58. Xiong, Y., G.J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
59. Zhang, Y. and Y. Xiong. 1999. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 3: 579-591.
60. Zindy, F., C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, and M.F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & Dev. 12: 2424-2433.